Phanes Therapeutics’ PT217 Receives FDA Fast Track Designation for NEPC Treatment Phanes Therapeutics announced that their drug PT217 has received Fast Track Designation from the FDA for neuroendocrine prostate cancer, enhancing its development prospects.

Phanes Therapeutics’ PT217 Receives FDA Fast Track Designation for NEPC Treatment #United_States #San_Diego #Phanes_Therapeutics #PT217 #FDA_Fast_Track